St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Citing projections that by 2030, America’s senior population will reach 20 percent of the population – 78 million people – and new survey information showing that Americans feel increasingly helpless about their personal cancer risk as they grow older, the American Institute for Cancer Research (AICR) today highlighted the emerging research showing that even in later life, many cancers can be delayed or prevented through regular physical activity and a plant-based diet.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/aicr/46620/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Valdoxan®/Thymanax® (agomelatine) is more efficacious than both conventional selective serotonin reuptake inhibitor (SSRI) and serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants, according to new data presented today at the 23rd European College of Neuropsychopharmacology (ECNP) Congress.
To view Multimedia News Release, go to http://maultivu.prnewswire.com/mnr/prne/valdoxan/44196/
Danica Patrick will take to the track with a new primary sponsor as the blue-and-white No. 10 Aspen Dental Chevrolet SS makes its debut at the Kobalt 400 NASCAR Sprint Cup Series race at Las Vegas Motor Speedway this weekend. And she’ll do it sporting a blue firesuit selected by fans who voted in the Danica's New Suit Sweepstakes.
Patrick first teamed up with Aspen Dental, one of the largest and fastest-growing networks of dental care providers in the U.S. with more than 430 locations in communities across 27 states, last fall. Since that time, she has helped to shine a spotlight on an often overlooked healthcare issue – oral health – by championing the launch of Aspen Dental's Healthy Mouth Movement, a community-giving initiative designed to deliver free dental care to thousands of people in need in communities across the U.S., and oral health education to millions more.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66081-aspen-dental-danica-patrick-new-primary-sponsor-las-vegas-motor-speedway
CVS/pharmacy, the nation’s leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced that flu vaccinations are now available at all of its locations nationwide. CVS/pharmacy has more than 7,000 locations and MinuteClinic has more than 500 locations inside select CVS/pharmacy stores.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvspharmacy/45561/
CVS/pharmacy and MinuteClinic announced their “You vs. Flu” campaign today. Flu vaccinations are now available at all CVS/pharmacy and MinuteClinic locations nationwide to help consumers win against the flu. CVS/pharmacy has more than 7,200 locations and MinuteClinic has nearly 600 locations inside select CVS/pharmacy stores.
Flu shots are being provided by CVS pharmacists and MinuteClinic nurse practitioners and physician assistants every day, including evenings and weekends, with no appointment necessary. The Centers for Disease Control and Prevention (CDC) recommends that everyone ages six months and older get a flu shot as soon as vaccine is available, including those who were vaccinated last flu season.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51328-cvs-minuteclinic-flu-shot
CVS Caremark and Children’s Hospital Boston will celebrate a mutually significant milestone at Fenway Park this evening. Just prior to the Boston Red Sox/Baltimore Orioles game, the two will recognize hitting the $1 million mark in funds donated to the Hospital by CVS Caremark for children with disabilities. The relationship that brought them to this point spans more than five years and focuses on a shared commitment to helping children with disabilities. Monies donated derive from the CVS Caremark Charitable Trust and the CVS Caremark All Kids Can Program and support the Hospital’s Cerebral Palsy Program and its Center for Communication Enhancement.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52103-cvs-caremark-reaches-1-million-in-donations-children-s-hospital-boston
An expert group of specialists have come together to develop three new educational resources: the Journal of Perioperative Medicine, the Journal of Neonatal Intensive Care and an open-access online portal. These resources provide practical advice on key clinical issues, tackle controversial topics on which a consensus is needed, and highlight clinical concerns that need to be addressed in clinical practice. These resources are available through a new educational initiative called Cure&Care and are accessible at: www.cureandcareportal.com. Cure&Care officially launches at Euroanaesthesia 2014, in Stockholm, Sweden, 30 May – 3 June.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400535-cure-care-new-educational-initiative
